![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 23, 2024
This phase 2 study will test a new treatment combination for patients with certain subtypes of relapsed or refractory B-cell lymphoma
December 23, 2024
Summaries of presentations at the 2024 San Antonio Breast Cancer Symposium as well as the 66th American Society of Hematology Annual Meeting and Exposition in San Diego
November 25, 2024
October 17, 2024
Summaries of recently published ECOG-ACRIN research results
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Summaries of recently published ECOG-ACRIN research results
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
December 22, 2021
Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
January 25, 2021
This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma